CompletedNCT00868452
Lurasidone added to mood stabilizers for depression in bipolarity
About this title
Read the official source — NCT00868452Medication studyAges 18–75Multiple countries
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 70 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 348
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Czechia, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00868452
- Official title
Show the full official title
A Randomized, 6-Week, Double-Blind, Placebo- Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedLittle Rock, United States · Anaheim, United States · Chino, United States
58 more locations
- Escondido, United States
- Garden Grove, United States
- Los Angeles, United States
- Orange, United States
- Pico Rivera, United States
- San Diego, United States
- Stanford, United States
- Aurora, United States
- Tampa, United States
- Oak Brook, United States
- Shreveport, United States
- Baltimore, United States
- Rockville, United States
- Saint Charles, United States
- Albuquerque, United States
- Raleigh, United States
- Cincinnati, United States
- Cleveland, United States
- Dayton, United States
- Philadelphia, United States
- Austin, United States
- Brno - Mesto, Czechia
- Litoměřice, Czechia
- Prague, Czechia
- Nîmes, France
- Orvault, France
- Berlin BE, Germany
- Tirupati, India
- Vijaywada, India
- Ahmedabad, India
- Jūnāgadh, India
- Bangalore, India
- Nashik, India
- Delhi, India
- Jaipur, India
- Lucknow, India
- Chełmno, Poland
- Skorzewo, Poland
- Warsaw, Poland
- Bucharest, Romania
- Cluj-Napoca, Romania
- Craiova, Romania
- Oradea, Romania
- Piteşti, Romania
- Moscow, Russia
- Saint Petersburg, Russia
- Cape Town, W. Cape, South Africa
- Paarl, W. Cape, South Africa
- Port Elizabeth, E. Cape, South Africa
- Pretoria, Gauteng, South Africa
- Vereeniging, Free State, South Africa
- Donetsk, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Simferopol, Ukraine
- Vinnitsia, Ukraine
- Czechia
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including lurasidone + (lithium or divalproex) and Placebo + (lithium or divalproex).
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
